Company Announcement no. 7/2012
To: NASDAQ OMX Copenhagen A/S Hoersholm, Denmark, 15 May, 2012
Veloxis Pharmaceuticals announces financial results for the first quarter 2012 in line with expectations, Phase III activities for LCP-Tacro' progressing according to plan
Highlights:
-- Enrolment has been completed in the pivotal LCP-Tacro 3002 Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus standard therapy Prograf® and randomized 543 patients at approximately 90 clinical sites around the world.
-- Veloxis have initiated the STRATO Study of LCP-Tacro' in Kidney Transplant Recipients Experiencing Tremors. The study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard immediate release twice-daily tacrolimus capsules to extended release once-daily LCP-Tacro' tablets leads to a measurable improvement in tremor.
-- Veloxis reported a net loss of DKK 75.0 million for the first quarter of 2012 compared to a net loss of DKK 65.8 million for the same period in 2011. The reported net loss is in line with expectations and the financial outlook for 2012 is maintained.
-- For the first quarter of 2012, Veloxis' research and development costs amounted to DKK 62.8 million compared to DKK 52.3 million during the same period in 2011.
-- On 31 March, 2012, Veloxis had cash and cash equivalents of DKK 213.8 million.
A conference call will be held tomorrow, 16 May, 2012 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM ET (New York), 6:00 AM PT (San Francisco).
To access the live conference call, please dial one of the following numbers:
+45 32 72 76 25 (Denmark)
+44 (0) 1452 555 566 (UK)
+1 631 510 7498 (USA)
Access code 77202811
Following the conference call, a recording will be available on the company's website http://www.veloxis.com.
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=392853
To: NASDAQ OMX Copenhagen A/S Hoersholm, Denmark, 15 May, 2012
Veloxis Pharmaceuticals announces financial results for the first quarter 2012 in line with expectations, Phase III activities for LCP-Tacro' progressing according to plan
Highlights:
-- Enrolment has been completed in the pivotal LCP-Tacro 3002 Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus standard therapy Prograf® and randomized 543 patients at approximately 90 clinical sites around the world.
-- Veloxis have initiated the STRATO Study of LCP-Tacro' in Kidney Transplant Recipients Experiencing Tremors. The study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard immediate release twice-daily tacrolimus capsules to extended release once-daily LCP-Tacro' tablets leads to a measurable improvement in tremor.
-- Veloxis reported a net loss of DKK 75.0 million for the first quarter of 2012 compared to a net loss of DKK 65.8 million for the same period in 2011. The reported net loss is in line with expectations and the financial outlook for 2012 is maintained.
-- For the first quarter of 2012, Veloxis' research and development costs amounted to DKK 62.8 million compared to DKK 52.3 million during the same period in 2011.
-- On 31 March, 2012, Veloxis had cash and cash equivalents of DKK 213.8 million.
A conference call will be held tomorrow, 16 May, 2012 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM ET (New York), 6:00 AM PT (San Francisco).
To access the live conference call, please dial one of the following numbers:
+45 32 72 76 25 (Denmark)
+44 (0) 1452 555 566 (UK)
+1 631 510 7498 (USA)
Access code 77202811
Following the conference call, a recording will be available on the company's website http://www.veloxis.com.
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=392853
© 2012 GlobeNewswire
